Literature DB >> 28815069

Three-field lymph node dissection in esophageal cancer surgery.

Satoru Matsuda1, Hiroya Takeuchi1,2, Hirofumi Kawakubo1, Yuko Kitagawa1.   

Abstract

Although multidisciplinary treatment has improved the prognosis of esophageal cancer, it is commonly associated with one of the worse prognoses. Since lymph node (LN) metastases can primarily occur from the cervical to the abdominal field, a strategy for extended LN dissection has been established. The three field LN dissection (3FD) during a transthoracic esophagectomy which is defined as a procedure for cervico-thoraco-abdominal LN dissection, was established in the 1980s' in Japan, and is currently widely accepted throughout the world. To date, various comparative trials between 3FD and two field LN dissections (2FD) have been reported and show that a transthoracic esophagectomy with 3FD is superior to 2FD for prognosis. However, in 3FD, postoperative complications, such as recurrent laryngeal nerve palsy and postoperative gastrointestinal dysfunction can be induced. Furthermore, there are few prospective trials that have compared between 2FD and 3FD. Therefore, to determine the ideal range of LN dissection, various factors (e.g., location of the primary tumor, disease progression, tumor histology, and perioperative treatment) must be considered. Recently, the efficacy of intense perioperative treatment for esophageal cancer has been reported, and the significance of minimally invasive surgical procedures are being verified. The ideal combination of perioperative treatment and feasible surgery must be established to improve the oncological outcome of esophageal cancer patients further.

Entities:  

Keywords:  Esophagectomy; esophageal cancer; three field lymph node (LN) dissection (3FD)

Year:  2017        PMID: 28815069      PMCID: PMC5538994          DOI: 10.21037/jtd.2017.03.171

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  50 in total

1.  Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands.

Authors:  Johan L Dikken; Valery E Lemmens; Michel W J M Wouters; Bas P Wijnhoven; Peter D Siersema; Grard A Nieuwenhuijzen; Johanna W van Sandick; Annemieke Cats; Marcel Verheij; Jan Willem Coebergh; Cornelis J H van de Velde
Journal:  Eur J Cancer       Date:  2012-02-06       Impact factor: 9.162

2.  Validation study of radio-guided sentinel lymph node navigation in esophageal cancer.

Authors:  Hiroya Takeuchi; Hirofumi Fujii; Nobutoshi Ando; Soji Ozawa; Yoshiro Saikawa; Koichi Suda; Takashi Oyama; Makio Mukai; Tadaki Nakahara; Atsushi Kubo; Masaki Kitajima; Yuko Kitagawa
Journal:  Ann Surg       Date:  2009-05       Impact factor: 12.969

3.  Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Yasuyuki Seto; Takeshi Sano; Hiroyasu Makuuchi; Nobutoshi Ando; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  2016-10-28       Impact factor: 7.370

4.  Thoracic recurrent laryngeal lymph node metastases predict cervical node metastases and benefit from three-field dissection in selected patients with thoracic esophageal squamous cell carcinoma.

Authors:  Hecheng Li; Su Yang; Yawei Zhang; Jiaqing Xiang; Haiquan Chen
Journal:  J Surg Oncol       Date:  2011-11-21       Impact factor: 3.454

5.  Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer.

Authors:  H Shiozaki; M Yano; T Tsujinaka; M Inoue; S Tamura; Y Doki; T Yasuda; Y Fujiwara; M Monden
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

6.  Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy.

Authors:  Hiromasa Fujita; Susumu Sueyoshi; Toshiaki Tanaka; Teruhiko Fujii; Uhi Toh; Takashi Mine; Hiroko Sasahara; Tomoya Sudo; Satoru Matono; Hideaki Yamana; Kazuo Shirouzu
Journal:  World J Surg       Date:  2003-04-28       Impact factor: 3.352

7.  Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.

Authors:  T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

8.  Cervical, mediastinal, and abdominal lymph node dissection (three-field dissection) for superficial carcinoma of the thoracic esophagus.

Authors:  H Kato; Y Tachimori; S Mizobuchi; H Igaki; A Ochiai
Journal:  Cancer       Date:  1993-11-15       Impact factor: 6.860

9.  Postoperative gastrointestinal dysfunction after 2-field versus 3-field lymph node dissection in patients with esophageal cancer.

Authors:  Misuzu Nakamura; Yoshihiro Kido; Yoshinori Hosoya; Masahiko Yano; Hideo Nagai; Morito Monden
Journal:  Surg Today       Date:  2007-04-30       Impact factor: 2.549

10.  Selective three-field lymphadenectomy for thoracic esophageal squamous carcinoma.

Authors:  W-T Fang; W-H Chen; Y Chen; Y Jiang
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429

View more
  17 in total

1.  The Number of Harvested LNs Is an Independent Prognostic Factor in Lymph Node Metastasis-negative Patients Who Received Curative Esophagectomy.

Authors:  Toru Aoyama; Yosuke Atsumi; Shinnosuke Kawahara; Hiroshi Tamagawa; Ayako Tamagawa; Yukio Maezawa; Kazuki Kano; Masaaki Murakawa; Keisuke Kazama; Masakatsu Numata; Takashi Oshima; Norio Yukawa; Munetaka Masuda; Yasushi Rino
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Impact of Regional Lymph Node Irradiation on Reducing Lymph Node Recurrence in Esophageal Cancer Patients.

Authors:  Shigenobu Watanabe; Ichiro Ogino; Daisuke Shigenaga; Masaharu Hata
Journal:  Cancer Diagn Progn       Date:  2022-03-03

3.  Clinical evaluation of right recurrent laryngeal nerve nodes in thoracic esophageal squamous cell carcinoma.

Authors:  Zhen-Xuan Li; Xiao-Dong Li; Xian-Ben Liu; Wen-Qun Xing; Hai-Bo Sun; Zong-Fei Wang; Rui-Xiang Zhang; Yin Li
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 2.895

4.  The clinical significance of the intraoperative pathological examination of bilateral recurrent laryngeal nerve lymph nodes using frozen sections in cervical field lymph node dissection of thoracic esophageal squamous cell carcinoma.

Authors:  Jinxin Xu; Bin Zheng; Shuliang Zhang; Taidui Zeng; Hao Chen; Wei Zheng; Chun Chen
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

Review 5.  Past, present, and future of three-field lymphadenectomy for thoracic esophageal cancer.

Authors:  Harushi Udagawa
Journal:  Ann Gastroenterol Surg       Date:  2020-05-14

6.  Prognostic impact of thoracic duct lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Satoru Matsuda; Hirofumi Kawakubo; Hiroya Takeuchi; Shuhei Mayanagi; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Norihito Wada; Yuko Kitagawa
Journal:  Ann Gastroenterol Surg       Date:  2021-01-19

Review 7.  Mediastinal lymphadenectomy for esophageal cancer: Differences between two countries, Japan and the Netherlands.

Authors:  Miguel A Cuesta; Donald L van der Peet; Suzanne S Gisbertz; Jennifer Straatman
Journal:  Ann Gastroenterol Surg       Date:  2018-05-01

8.  Impact of high body mass index on surgical outcomes and long-term survival among patients undergoing esophagectomy: A meta-analysis.

Authors:  Hua Gao; Hai-Ming Feng; Bin Li; Jun-Ping Lin; Jian-Bao Yang; Duo-Jie Zhu; Tao Jing
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

9.  Comparison of the short-term outcomes of robot-assisted minimally invasive, video-assisted minimally invasive, and open esophagectomy.

Authors:  Lei Gong; Hongjing Jiang; Jie Yue; Xiaofeng Duan; Peng Tang; Peng Ren; Xijiang Zhao; Xiangming Liu; Xi Zhang; Zhentao Yu
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

10.  Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma.

Authors:  Ayesha Noorani; Xiaodun Li; Martin Goddard; Jason Crawte; Ludmil B Alexandrov; Maria Secrier; Matthew D Eldridge; Lawrence Bower; Jamie Weaver; Pierre Lao-Sirieix; Inigo Martincorena; Irene Debiram-Beecham; Nicola Grehan; Shona MacRae; Shalini Malhotra; Ahmad Miremadi; Tabitha Thomas; Sarah Galbraith; Lorraine Petersen; Stephen D Preston; David Gilligan; Andrew Hindmarsh; Richard H Hardwick; Michael R Stratton; David C Wedge; Rebecca C Fitzgerald
Journal:  Nat Genet       Date:  2020-01-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.